Tumor Necrosis Factor Ligand Superfamily Member 14 Total (LIGHT Total)
Ultrasensitive Immunoassay
Rules-Based Medicine’s internally developed and manufactured ultrasensitive immunoassay to tumor necrosis factor ligand superfamily member 14 total (LIGHT, TNFSF14) based on the Simoa® bead technology can accurately quantitate sub-pg/mL levels of total LIGHT in human serum and plasma. Such sensitive detection may be useful for clinical studies related to cancer, graft vs host disease, coronary artery disease, and multiple myeloma associated bone disease.
LIGHT, also known as TNFSF14 and CD258, is a secreted protein of TNF superfamily. LIGHT is expressed by activated lymphocytes, natural killer cells, immature dendritic cells, monocytes, and granulocytes. LIGHT stimulates the proliferation of T cells, triggers apoptosis of various tumor cells, and prevents TNF-a mediated apoptosis in primary hepatocytes. LIGHT signaling occurs via two distinct receptors; herpes virus entry mediator (HVEM)/TNFRSF14 and the lymphotoxin-b receptor (LTBR)/TNFRSF3. Alternatively, TNFSF14 can also bind to the soluble decoy receptor 3 (DcR3)/TNFRSF6B. Signaling through LTBR induces apoptosis, on the other hand, signaling through HVEM activates T helper cell type 1 (TH1) mediated immune responses, and augments cytotoxic T lymphocytes (CTL)-mediated antitumor immunity. LIGHT induced apoptosis can be enhanced by IFN-gamma.
LIGHT is known to regulate allogeneic T cell activation and allograft rejection, and antibody mediated blockade of HVEM signaling has been shown to prevent graft versus host disease. Increased overexpression of LIGHT enhances anti-tumor immune responses and is correlated with the survival of patients in certain cancers. In stable coronary artery disease (CAD), LIGHT correlates with the risk of cardiovascular events. Additionally, LIGHT may be a potent therapeutic target to modulate inflammation in inflammatory diseases.
Swiss-Prot Accession Number: O43557
Alternate names for this biomarker include:
Herpes virus entry mediator ligand, HVEM-L, CD258
| Biomarker | LLOQ* (Serum and Plasma) |
LLOQ* (Undiluted Samples) |
Volume Required | |
|---|---|---|---|---|
| Serum or plasma | Other fluids** | |||
| Tumor Necrosis Factor Ligand Superfamily Member 14 Total (LIGHT Total) | 0.56 pg/mL | 0.14 pg/mL | 100 µL | 150 µL |
* Lower limit of quantitation (LLOQ) represents the lowest amount of an analyte that can be quantitatively determined with acceptable precision. LLOQ is determined by performing 2-fold serial dilutions of Standard to be tested in triplicate over three runs. The percent coefficient of variation (CV) is calculated for each of the dilution replicates, and the LLOQ is determined as the concentration at which the CV is 30%.
** Cerebrospinal fluid, urine, tissue culture supernatants, bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.
All assay services are performed in our CLIA-certified laboratory.
Intended for Research Use Only.